CONNECT WITH US
HealthTech

HealthTech

Senseonics, Beta Bionics integrate diabetes technology

MedTech Dive logo

Published on

Add as a preferred source on Google
Senseonics, Beta Bionics integrate diabetes technology

The collaboration, combining Senseonics’ implantable glucose sensor with Beta Bionics’ insulin pump, is intended to simplify diabetes management.

The integration is intended to make it easier for people to manage their diabetes and expand their device choices.

Senseonics’ implantable design, with fewer sensor changes and high accuracy even at low glucose levels, makes it well suited for automated insulin delivery, the companies said in a statement. Meanwhile, Beta Bionics’ iLet device is intended to minimize the need for carb counting or manual correction boluses. Beta Bionics Chief Commercial Officer Mark Hopman said in a statement that the partnership should help reduce the “constant work and decision-making that can come with managing diabetes.”

Currently, Senseonics’ Eversense 365 CGM is integrated with one other pump, Sequel Med Tech’s twist automated insulin delivery system. In an earnings call earlier this month, Senseonics Chief Commercial Officer Brian Hansen said the Sequel partnership has benefited both companies almost one year later. The lack of pump compatibility was a reason people discontinued using Senseonics sensors, so adding a second option “is very exciting for us.”

Beta Bionics’ iLet pump, for its part, is also compatible with sensors made by Abbott and Dexcom. The company received FDA clearance for its first insulin patch pump, Mint, in September. Beta Bionics is planning a full U.S. launch of the device for the first quarter of 2027.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.